Exhibit 99.1

 

PRESS RELEASE

 

 

Contacts:   Alfred J. Novak
    Chief Executive Officer
    (770) 717-6096

 

NOVOSTE ANNOUNCES THIRD QUARTER 2004

FINANCIAL RESULTS

 

NORCROSS, GA., November 3, 2004

– Novoste Corporation (NASDAQ: NOVT) today reported its financial results for the quarter ended September 30, 2004.

 

The Company reported that GAAP (Generally Accepted Accounting Principles) net revenue for the third quarter 2004 was $6.0 million compared to $13.5 million for the third quarter 2003. Revenues continue to be negatively impacted by the sales of drug-eluting stents (DES) and their aggressive use by physicians as an alternative therapy for in-stent restenosis. Additionally, a revenue reserve of $0.4 million was recognized in the prior year quarter as the 3.5 French products were exchanged for 5 French products sold in earlier periods. There was no comparable revenue reserve adjustment in the third quarter 2004; therefore net revenue of $6.0 million in the current quarter can be compared to third quarter 2003 adjusted net revenue of $13.1 million. A reconciliation of GAAP to “as adjusted” financial data is included in the attached financial statements. The conversion of Guidant accounts in the United States and Canada to the Novoste Beta-Cath System is ongoing and helped to slightly increase third quarter net revenue of $6.0 million compared to the second quarter 2004 net revenue of $5.8 million, in spite of the impact of DES. A decline in catheter unit sales was offset by the increase in revenue being attributed to the ability to charge for the service and lease costs associated with the radiation component of the Beta-Cath system and an increased catheter price.

 

The Company booked a $0.9 million non-cash impairment charge in the current quarter to reflect the reduced book value of its radiation source train (RST) plant. This charge represents management’s best estimate of potential impairment at this time given the declining market for vascular brachytherapy, and the Company’s suspension of production of RSTs, as it is able to meet near term RST needs from existing inventories. The carrying net book value of the RST plant before the charge was $2.8 million.

 

Excluding this non-cash impairment charge, gross margin as adjusted, for the third quarter 2004 was 27% as compared to an adjusted gross margin of 58% for the third quarter of 2003. The decrease in margin is a function of the significantly lower volume of procedures and high fixed costs. Operating expenses were $6.1 million for the third quarter 2004, down from $9.6 million in the third quarter of 2003. Research and development (R&D) expenses were $0.8 million, down from $3.2 million in the third quarter 2003, reflecting decreased spending on engineering and clinical trials. Selling, general and administrative (SG&A) expenses were $5.3 million in the quarter, down from $6.4 million in the third quarter 2003. The decrease in SG&A and other expenses is a result of the reduction in force and other ongoing measures taken by management to lower the Company’s cost structure.

 

1


The following information was filed by Novt Corp (NVTP) on Wednesday, November 3, 2004 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Novt Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novt Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account